Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 184 across all filing types
Latest filing 2022-04-29 Report Publication Anno…
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
NFL Biosciences : Mise à disposition du Rapport Annuel au 31/12/2021
Report Publication Announcement Classification · 99% confidence The document is titled "NFL Biosciences : Mise à disposition du Rapport Annuel au 31/12/2021" (NFL Biosciences: Availability of the Annual Report as of 12/31/2021). It explicitly states that the company has made its Annual Report for the year ended 12/31/2021 available to the public and filed it with the AMF on April 29, 2022. The document itself is very short (2027 characters) and serves primarily to announce the publication of the full Annual Report, rather than containing the full content of the 10-K or AR. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published points to a Report Publication Announcement (RPA). Although the content relates to the Annual Report (10-K), the document's function here is the announcement of its release.
2022-04-29 French
NFL BIOSCIENCES : Décision d’accord de délivrance de son brevet en Chine
Regulatory Filings Classification · 100% confidence The document is a press release from NFL BIOSCIENCES announcing that it has received a patent grant decision from the Chinese National Intellectual Property Administration (CNIPA) for its drug candidate NFL-101. This announcement concerns the protection of intellectual property (a patent) for a specific drug candidate. This type of announcement, which details legal protection or intellectual property rights, does not fit neatly into standard financial reporting categories like 10-K, ER, or IR. It is a specific corporate update related to legal/IP strategy. Since there is no specific code for 'Intellectual Property Grant Announcement', and it is a formal announcement regarding a legal/regulatory outcome concerning the company's assets, it is best classified as a general Regulatory Filing (RNS) or potentially a Legal Proceedings Report (LTR) if the patent grant was contested, but RNS is the more appropriate general regulatory announcement fallback for non-standard filings. Given the focus on patent protection, it is a specific corporate action announcement, making RNS the most suitable general category.
2022-04-11 French
NFL BIOSCIENCES: Notice of allowance of its patent in China
Regulatory Filings Classification · 100% confidence The document is a press release titled "NFL BIOSCIENCES: Notice of allowance of its patent in China." It details the granting of a patent by the Chinese National Intellectual Property Administration (CNIPA) for their drug candidate NFL-101. This announcement concerns intellectual property rights and regulatory/legal protection for a product, which falls under the scope of legal proceedings or specific regulatory updates, but is most closely aligned with general regulatory announcements or legal matters. Since it is a specific announcement about a patent allowance, it is not a standard financial report (10-K, IR, ER) or a management change (MANG). It is a specific regulatory/legal event notification. Given the options, 'Legal Proceedings Report (LTR)' covers significant lawsuits or regulatory actions, and a patent allowance is a significant regulatory/IP event. However, if the document is purely an announcement of a non-financial regulatory event that doesn't fit other specific categories (like DIRS, DIV, CAP), 'Regulatory Filings (RNS)' serves as the best general regulatory announcement fallback. Since the core topic is the granting of a patent, which is a regulatory/legal milestone, and there is no specific code for 'Patent Grant Announcement', RNS is the most appropriate general regulatory category for this type of news release, as it is not a financial report or a management/governance document.
2022-04-11 English
NFL Biosciences : Activités & Résultats annuels 2021
Earnings Release Classification · 99% confidence The document is explicitly titled "NFL Biosciences : Activités & Résultats annuels 2021" and details the company's activities and financial results for the full year ending December 31, 2021. It includes a detailed comparative table of annual financial accounts, mentions the finalization of audit procedures, and discusses the annual report preparation process ("Les Rapports des commissaires aux comptes seront émis après finalisation du Rapport de gestion, préalablement à la publication du Rapport Financier Annuel"). Although it mentions the audit report issuance is pending, the core content is the comprehensive annual performance review and financial statements for the fiscal year. This aligns best with the Annual Report (10-K) definition, which covers full company activity and financial performance for the year. Since this is a French company filing on Euronext Growth, it is the local equivalent of a 10-K, which is classified as '10-K' in our system for comprehensive annual reports. FY 2021
2022-03-28 French
NFL BIOSCIENCES: co-development agreement for a drug candidate to reduce alcohol consumption
Regulatory Filings Classification · 91% confidence The document is a 'PRESS RELEASE' dated February 2, 2022, announcing a 'co-development agreement' between NFL Biosciences and ATHENA Pharmaceutiques regarding a drug candidate (NFL-301) for reducing alcohol consumption. This is a specific corporate action announcement detailing a partnership, investment, and future clinical plans. It is not a comprehensive annual report (10-K), an earnings release (ER), a formal regulatory filing like a proxy statement (DEF 14A), or a transcript (CT). Since it announces a significant business development (a partnership/financing aspect), it fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if no other category fits. Given the focus on a 'co-development agreement' involving joint investment and sharing future revenues, it strongly relates to capital structure/financing activities, making CAP a plausible fit, although it is primarily a strategic announcement. However, looking at the definitions, none perfectly capture a strategic partnership announcement unless it involves a direct capital raise or M&A. Since it details a business agreement and future development funding structure, and it is not a standard financial report, it is most appropriately classified as a general Regulatory Filing (RNS) as it is a material, non-standard announcement, or potentially CAP if the partnership is viewed as a financing mechanism. Given the options, and that it's a press release announcing a material business development that isn't explicitly covered by the other specific financial/reporting codes, RNS (Regulatory Filings - general fallback) is the safest classification, although it shares characteristics with CAP. I will lean towards RNS as it is a general corporate announcement/press release.
2022-02-02 English
NFL BIOSCIENCES : accord de co-développement d’un candidat médicament pour réduire la consommation d’alcool
Regulatory Filings Classification · 94% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a co-development agreement between NFL Biosciences and ATHENA Pharmaceutiques regarding a drug candidate (NFL-301) for reducing alcohol consumption. It details the partnership terms, market potential, and includes quotes from management. This type of announcement, focusing on a specific business development (a partnership/deal) rather than comprehensive financial results (10-K, IR, ER) or a general regulatory update (RNS), fits best under Capital/Financing Update (CAP) if it involves significant financial commitment or M&A Activity (TAR) if it were a merger. However, since it is a specific business development agreement concerning drug development and investment sharing, and it is presented as a press release announcing a strategic move, it is most closely aligned with a general corporate announcement. Given the options, and since it is not a formal regulatory filing like a 10-K or a specific report like an ER or IR, it falls into the category of a significant corporate event announcement. While 'CAP' relates to financing, this is primarily a co-development deal. 'RNS' is the fallback for general regulatory announcements. Given the nature of the announcement (a strategic partnership/deal), and lacking a more specific category for 'Partnership Announcement', 'RNS' (Regulatory Filings/General Announcement) is the most appropriate general classification for a press release detailing a strategic business agreement that isn't a formal financial report or a specific insider/dividend notice. However, if we strictly interpret the definitions, this is a major corporate event announcement. Since it is a press release announcing a strategic business development (co-development agreement), and it is not a formal financial report, the closest fit among the specific options is difficult. It is not a DIRS, DIV, DLST, or DEF 14A. It is not an ER or IR. It is a press release announcing a deal. In many databases, such announcements default to a general filing category. I will classify it as RNS as the best general corporate announcement fallback, as it is a 'COMMUNIQUÉ DE PRESSE' and not one of the highly specific report types.
2022-02-02 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.